Leap Therapeutics (LPTX) Downgraded to “Hold” at Zacks Investment Research
Leap Therapeutics (NASDAQ:LPTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “
Shares of Leap Therapeutics (NASDAQ:LPTX) opened at $6.28 on Friday. Leap Therapeutics has a 52 week low of $4.90 and a 52 week high of $10.10.
In related news, COO Augustine Lawlor acquired 1,057,769 shares of the stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 58.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Leap Therapeutics (LPTX) Downgraded to “Hold” at Zacks Investment Research” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/leap-therapeutics-lptx-downgraded-to-hold-at-zacks-investment-research/1806900.html.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.